NYSEAM:PLXBiotechs
Protalix BioTherapeutics (PLX) TTM Loss Challenges Bullish Profitability Narratives After FY 2025 Results
Protalix BioTherapeutics FY 2025 Earnings Snapshot
Protalix BioTherapeutics (PLX) has wrapped up FY 2025 with fourth quarter revenue of US$9.1 million and a basic EPS loss of US$0.07, as investors weigh the latest numbers against the share price of US$2.21. The company has seen quarterly revenue move from US$18.2 million in Q4 2024 to US$10.1 million in Q1 2025, US$15.7 million in Q2 2025, US$17.9 million in Q3 2025 and US$9.1 million in Q4 2025. Basic EPS shifted from US$0.09 in Q4 2024 to...